Novo Nordisk Challenges Eli Lilly Over Advertising Claims for Weight-Loss Drugs

Novo Nordisk has formally challenged Eli Lilly’s marketing practices, alleging that its competitor is using misleading data to compare the efficacy of their respective weight-loss and diabetes treatments. The dispute centers on how Eli Lilly frames clinical results in its promotional materials for Mounjaro and Zepbound against Novo Nordisk’s Ozempic and Wegovy. According to a report from Reuters, Novo Nordisk has raised these concerns with the National Advertising Division (NAD) of BBB National Programs, a self-regulatory body that reviews advertising truthfulness.

The Basis of the Advertising Dispute

The conflict involves how Eli Lilly characterizes the performance of its tirzepatide-based products (Mounjaro and Zepbound) relative to semaglutide-based products (Ozempic and Wegovy). Novo Nordisk contends that Eli Lilly’s advertisements use indirect comparisons that lack sufficient head-to-head clinical trial data to support the claims of superiority. In the pharmaceutical industry, comparisons between drugs are typically regulated by strict guidelines; firms must generally rely on head-to-head trials—where patients are directly randomized into two groups—to make definitive claims about one drug performing better than another.

Novo Nordisk asserts that Eli Lilly’s marketing materials utilize network meta-analyses or other indirect comparisons that do not meet the standard required for such public claims. By doing so, Novo Nordisk argues that the advertisements could potentially confuse physicians and patients regarding the relative clinical profiles of these medications.

Regulatory Oversight and Industry Standards

The National Advertising Division (NAD) serves as an industry-funded mechanism to resolve disputes before they escalate to federal regulators like the U.S. Food and Drug Administration (FDA) or the Federal Trade Commission (FTC). While the FDA oversees the accuracy of pharmaceutical labeling and promotional materials, the NAD focuses on the truthfulness and substantiation of advertising claims in the broader marketplace.

According to BBB National Programs, the NAD provides a forum for competitors to challenge each other’s claims. If the NAD finds that an advertisement lacks the necessary scientific backing, it can recommend that the company modify or discontinue the campaign. While these recommendations are voluntary, most major corporations comply to avoid formal investigations from federal agencies.

Comparison of GLP-1 Receptor Agonists

Both companies produce medications in the GLP-1 receptor agonist class, which have seen a surge in demand for the treatment of type 2 diabetes and chronic weight management. The following table summarizes the primary drug products involved in the current market competition:

Tirzepatide is a dual GLP-1 and GIP receptor agonist, whereas semaglutide acts primarily as a GLP-1 receptor agonist. While both have shown significant efficacy in clinical trials for weight loss and blood glucose control, the interpretation of data regarding their relative performance remains a subject of intense commercial and clinical debate.

Looking Ahead

The outcome of the NAD review will likely hinge on whether Eli Lilly can provide adequate scientific substantiation for the specific comparisons used in its advertisements. As both companies continue to expand their manufacturing capacity to meet record-high demand, the scrutiny of their marketing practices is expected to remain high. Neither company has publicly disclosed the specific advertisements targeted in the challenge, but the process highlights the ongoing tension between these two pharmaceutical giants as they compete for dominance in the weight-loss drug market.